JP2005517412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517412A5 JP2005517412A5 JP2003568094A JP2003568094A JP2005517412A5 JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5 JP 2003568094 A JP2003568094 A JP 2003568094A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antisense oligonucleotide
- nephropathy
- activity
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35637402P | 2002-02-12 | 2002-02-12 | |
| PCT/US2003/004186 WO2003068983A1 (en) | 2002-02-12 | 2003-02-12 | Use of the axl receptor for diagnosis and treatment of renal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517412A JP2005517412A (ja) | 2005-06-16 |
| JP2005517412A5 true JP2005517412A5 (enExample) | 2006-04-13 |
Family
ID=27734638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003568094A Pending JP2005517412A (ja) | 2002-02-12 | 2003-02-12 | 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20030157573A1 (enExample) |
| EP (1) | EP1483400A4 (enExample) |
| JP (1) | JP2005517412A (enExample) |
| CN (1) | CN1646695A (enExample) |
| AU (1) | AU2003223172A1 (enExample) |
| IL (1) | IL163547A0 (enExample) |
| WO (1) | WO2003068983A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223172A1 (en) * | 2002-02-12 | 2003-09-04 | Quark Biotech, Inc. | Use of the axl receptor for diagnosis and treatment of renal disease |
| EP1563094A4 (en) * | 2002-10-29 | 2007-04-25 | Rigel Pharmaceuticals Inc | MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS |
| CA2561073C (en) | 2004-03-27 | 2014-01-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| TW200726845A (en) * | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
| CA2710051C (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| EP2170395A1 (en) * | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| CA3056999A1 (en) | 2010-01-22 | 2011-07-28 | Amato J. Giaccia | Inhibition of axl signaling in anti-metastatic therapy |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| SG11201404505PA (en) | 2012-01-31 | 2014-10-30 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| EP2626705A1 (en) * | 2012-02-13 | 2013-08-14 | Institut d'Investigacions Biomédiques August Pi i Sunyer | Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome |
| US9801880B2 (en) * | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EA201790696A1 (ru) * | 2014-10-20 | 2017-10-31 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| US11353465B2 (en) | 2017-01-12 | 2022-06-07 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CN113215157B (zh) * | 2021-05-20 | 2022-06-21 | 徐州医科大学 | 特异性靶向人AXL基因的sgRNA及其应用 |
| CN113252911B (zh) * | 2021-07-02 | 2021-12-10 | 珠海丽珠试剂股份有限公司 | SARS-CoV-2中和抗体的检测试剂盒及其应用 |
| KR102763266B1 (ko) * | 2021-11-30 | 2025-02-04 | 충남대학교산학협력단 | Axl을 포함하는 지방간 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| CA2175893C (en) * | 1993-11-23 | 2010-06-22 | Paul J. Godowski | Protein tyrosine kinases named rse |
| WO1995019570A1 (en) * | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5538861A (en) * | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US6211142B1 (en) * | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
| US5849585A (en) * | 1995-05-10 | 1998-12-15 | Genetech, Inc. | Isolating and culturing Schwann cells |
| US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
| US6236769B1 (en) * | 1998-01-28 | 2001-05-22 | Cognex Corporation | Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| JP2005527639A (ja) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Ｒｎａ干渉の治療的利用のための方法及び組成物 |
| AU2003223172A1 (en) * | 2002-02-12 | 2003-09-04 | Quark Biotech, Inc. | Use of the axl receptor for diagnosis and treatment of renal disease |
| US20030229906A1 (en) * | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| JP2007524349A (ja) * | 2003-01-16 | 2007-08-30 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法 |
-
2003
- 2003-02-12 AU AU2003223172A patent/AU2003223172A1/en not_active Abandoned
- 2003-02-12 US US10/365,135 patent/US20030157573A1/en not_active Abandoned
- 2003-02-12 IL IL16354703A patent/IL163547A0/xx unknown
- 2003-02-12 JP JP2003568094A patent/JP2005517412A/ja active Pending
- 2003-02-12 WO PCT/US2003/004186 patent/WO2003068983A1/en not_active Ceased
- 2003-02-12 EP EP03719300A patent/EP1483400A4/en not_active Withdrawn
- 2003-02-12 CN CNA038082365A patent/CN1646695A/zh active Pending
-
2007
- 2007-07-10 US US11/827,198 patent/US20090075923A1/en not_active Abandoned
-
2008
- 2008-01-07 US US12/006,999 patent/US20090042826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023058575A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2023519140A5 (enExample) | ||
| JP2017536119A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2010533171A5 (enExample) | ||
| JP2009506124A5 (enExample) | ||
| JP2009511034A5 (enExample) | ||
| JP2008513513A5 (enExample) | ||
| JP2010526153A5 (enExample) | ||
| JP2005517430A5 (enExample) | ||
| WO2007134014A3 (en) | Compounds and methods for modulating expression of gcgr | |
| JP2012505657A5 (enExample) | ||
| JP2005500025A5 (enExample) | ||
| EP1799859A4 (en) | IMPROVED ANTISENSE OLIGONUCLEOTIDE | |
| WO2008008433A3 (en) | Substituted acylanilides and methods of use thereof | |
| JP2012105686A5 (enExample) | ||
| JP2009544281A5 (enExample) | ||
| EP2062586A3 (en) | Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors | |
| IL262728B1 (en) | Oligonucleotides conjugated to the ligand complex of the glp-1 receptor and their uses | |
| JP2022537987A5 (enExample) | ||
| JP2007517498A5 (enExample) | ||
| JP2006510659A5 (enExample) | ||
| EP1185696A4 (en) | MODIFICATION OF THE EXPRESSION OF THE HUMAN PROTEIN KINASE C-DELTA WITH THE HELP OF ANTISENSE OLIGONUCLEOTIDS | |
| WO2002103014A3 (fr) | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires |